Q4 2024 |
686 |
$528M |
+$21.4M |
-$15.8M |
+$5.63M |
DRSK, ACIO, SPLG, JUCY, VIGI
|
13F-HR |
1/10/2025, 02:26 PM |
Q3 2024 |
673 |
$528M |
+$24.3M |
-$14.4M |
+$9.94M |
DRSK, ACIO, VIGI, JUCY, SPLG
|
13F-HR |
10/8/2024, 09:31 AM |
Q2 2024 |
663 |
$493M |
+$11.8M |
-$5.85M |
+$5.93M |
DRSK, ACIO, JUCY, VIGI, SPLG
|
13F-HR |
7/8/2024, 12:02 PM |
Q1 2024 |
668 |
$482M |
+$59.7M |
-$12.3M |
+$47.3M |
DRSK, ACIO, JUCY, VIGI, SPLG
|
13F-HR |
4/23/2024, 09:52 AM |
Q4 2023 |
681 |
$414M |
+$12.4M |
-$26M |
-$13.5M |
DRSK, JUCY, ACIO, VIGI, OSCV
|
13F-HR |
1/10/2024, 11:56 AM |
Q3 2023 |
703 |
$395M |
+$46.3M |
-$61.9M |
-$15.7M |
DRSK, JUCY, ACIO, VIGI, OSCV
|
13F-HR |
11/13/2023, 09:20 AM |
Q2 2023 |
687 |
$427M |
+$23.5M |
-$11.4M |
+$12M |
DRSK, ACIO, JUCY, OSCV, VIGI
|
13F-HR |
7/13/2023, 09:45 AM |
Q1 2023 |
695 |
$406M |
+$38.3M |
-$40.9M |
-$2.61M |
DRSK, ACIO, JUCY, OSCV, VIGI
|
13F-HR |
4/26/2023, 01:48 PM |
Q4 2022 |
780 |
$398M |
+$62.5M |
-$68.5M |
-$5.98M |
DRSK, ACIO, ADME, JUCY, OSCV
|
13F-HR |
2/3/2023, 10:51 AM |
Q3 2022 |
693 |
$387M |
+$19.7M |
-$7.25M |
+$12.4M |
DRSK, ACIO, ADME, OSCV, IDUB
|
13F-HR |
10/11/2022, 02:56 PM |
Q2 2022 |
724 |
$399M |
+$72M |
-$41.1M |
+$30.9M |
DRSK, ACIO, ADME, IDUB, OSCV
|
13F-HR |
7/11/2022, 07:01 PM |
Q1 2022 |
673 |
$422M |
+$23.7M |
-$3.3M |
+$20.4M |
DRSK, ACIO, ADME, OSCV, IDUB
|
13F-HR |
4/25/2022, 04:22 PM |
Q4 2021 |
712 |
$422M |
+$21.8M |
-$3.09M |
+$18.7M |
DRSK, ACIO, ADME, OSCV, IDUB
|
13F-HR |
1/20/2022, 01:07 PM |
Q3 2021 |
731 |
$380M |
+$37.9M |
-$18.1M |
+$19.7M |
DRSK, ACIO, ADME, OSCV, IDUB
|
13F-HR |
10/20/2021, 12:09 PM |
Q2 2021 |
722 |
$367M |
+$55M |
-$7.83M |
+$47.1M |
DRSK, ADME, ACIO, OSCV, IEFA
|
13F-HR |
7/20/2021, 10:34 AM |
Q1 2021 |
625 |
$262M |
+$18.7M |
-$1.18T |
-$1.18T |
DRSK, ACIO, ADME, OSCV, RSP
|
13F-HR |
4/19/2021, 04:32 PM |
Q4 2020 |
669 |
$298M |
+$12.7M |
-$5.26M |
+$7.43M |
DRSK, ADME, ACIO, AGG, ITOT
|
13F-HR |
2/3/2021, 02:20 PM |
Q3 2020 |
620 |
$272M |
+$36.9M |
-$24.4M |
+$12.5M |
DRSK, ADME, ACIO, AGG, ITOT
|
13F-HR |
11/3/2020, 12:59 PM |
Q2 2020 |
633 |
$256M |
+$20.9M |
-$5.84M |
+$15.1M |
DRSK, ADME, ACIO, AGG, QQQ
|
13F-HR |
7/20/2020, 06:07 PM |
Q1 2020 |
638 |
$220M |
+$48.3M |
-$25.4M |
+$22.9M |
DRSK, ACIO, ADME, AGG, IEFA
|
13F-HR |
4/15/2020, 11:19 AM |
Q4 2019 |
665 |
$235M |
|
|
|
DRSK, ADME, ACIO, ITOT, OSCV
|
13F-HR |
1/29/2020, 01:26 PM |